Related Experiment Video
Updated: Dec 27, 2025

Multicellular Human Alveolar Model Composed of Epithelial Cells and Primary Immune Cells for Hazard Assessment
Published on: May 6, 2020
Towards an animal-free human health assessment: starting from the current regulatory needs
Peter M J Bos1, Liesbeth Geraets1, Lianne De Wit-Bos1
1National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Abstract:
Societal concern for animal welfare and scientific concerns about the predictive power of animal models for the human situation are driving forces for the development of animal-free approaches for the safety testing of chemicals. A paradigm shift towards an assessment of human health risks that is fully based on non-animal approaches is not foreseen within the next decades. To accelerate the use of non-animal innovations (e.g. in vitro experiments, in silico methods etc) in the EU, it has multiple advantages to simultaneously work towards a new risk assessment paradigm and to aim their development at better meeting the current regulatory needs. To achieve this, a multi-stakeholder collaboration is needed already in the development phase of animal-free innovations, where regulators can inform on the regulatory needs and the criteria for acceptance. As a first step, the present paper discusses what basic information is needed within the context of four areas of chemical safety assessment in the EU: 1) classification, labelling and packaging, 2) the derivation of health-based guidance values and product limits, 3) risk assessments of exposure situations of concern and 4) addressing specific topics of societal concern. Further agreements on the level of detail and uncertainty, robustness, predictive value, reproducibility and validation are a prerequisite to develop tools that can be trusted and that will be legally binding.
Related Concept Videos
Drug Regulation
Preclinical Development: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Bioavailability Study Design: Healthy Subjects Versus Patients
Clinically Relevant Drug Product Specifications: Methods of Establishment
Bioequivalence studies: Biowaivers

